Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis

Go Anan^{1

2}, Daisuke Kikuchi³, Takuo Hirose^{4

5

6}, Hiroki Ito⁴, Shingo Nakayama⁴, Takefumi Mori^{4

5}

Affiliations

¹ Department of Urology, Yotsuya Medical Cube, Tokyo, Japan.
² Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan.
³ Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
⁴ Division of Nephrology and Endocrinology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
⁵ Division of Integrative Renal Replacement Therapy, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
⁶ Department of Endocrinology and Applied Medical Science, Tohoku University Graduate School of Medicine, Sendai, Japan.

Go Anan et al. Kidney Int Rep. 2023.

. 2023 Feb 3;8(4):925-928.

doi: 10.1016/j.ekir.2023.01.034. eCollection 2023 Apr.

Go Anan^{1

2}, Daisuke Kikuchi³, Takuo Hirose^{4

5

6}, Hiroki Ito⁴, Shingo Nakayama⁴, Takefumi Mori^{4

5}

¹ Department of Urology, Yotsuya Medical Cube, Tokyo, Japan.
² Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan.
³ Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
⁴ Division of Nephrology and Endocrinology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
⁵ Division of Integrative Renal Replacement Therapy, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
⁶ Department of Endocrinology and Applied Medical Science, Tohoku University Graduate School of Medicine, Sendai, Japan.

No abstract available

Keywords: diabetes; epidemiologic study; inflammation; metabolic syndrome; sodium-glucose cotransporter-2 inhibitor; urolithiasis.

References

1. Taylor E.N., Stampfer M.J., Curhan G.C. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68:1230–1235. doi: 10.1111/j.1523-1755.2005.00516.x. - DOI - PubMed
1. Terami N., Ogawa D., Tachibana H., et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9 doi: 10.1371/journal.pone.0100777. - DOI - PMC - PubMed
1. Anan G., Hirose T., Kikuchi D., et al. Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation. Pharmacol Res. 2022;186 doi: 10.1016/j.phrs.2022.106524. - DOI - PubMed
1. Kristensen K.B., Henriksen D.P., Hallas J., Pottegård A., Lund L.C. Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis. Diabetologia. 2021;64:1563–1571. doi: 10.1007/s00125-021-05424-4. - DOI - PubMed
1. Balasubramanian P., Wanner C., Ferreira J.P., et al. Empagliflozin and decreased risk of nephrolithiasis: a potential new role for SGLT2 inhibition? J Clin Endocrinol Metab. 2022;107:e3003–e3007. doi: 10.1210/clinem/dgac154. - DOI - PMC - PubMed